Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma

• Status: Not yet recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess if regular use of tiotropium (i.e. daily) results in loss of bronchoprotection against methacholine induced bronchoconstriction in those with mild asthma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Saskatchewan
• Treatments: Bromides; Tiotropium Bromide

Criteria

Inclusion Criteria:

• diagnosis of asthma

• asthma is currently well controlled using only occasional bronchodilators

• baseline lung function (FEV1) is greater than 65% of the predicted value

• exhibit bronchoconstriction to inhaled methacholine at a dose of 200mcg or less

Exclusion Criteria:

• women who are pregnant or breastfeeding.

• diagnosis of another lung condition or medical condition that would pose a risk to the participant if enrolled in the study

• current smokers of nicotine products (e.g., cigarettes).

• users of cannabis or other inhaled recreational products (e.g., e-cigarettes or other vaping products) on a daily basis

• respiratory infection within 4 weeks of entering the study

• use of any anticholinergic agent within 30 days prior to the beginning of the study (e.g., ipratropium or the study treatment tiotropium).

• known hypersensitivity to tiotropium bromide or components of tiotropium formulation (e.g., benzalkonium chloride), to atropine or its derivatives.